时间标签:数据日期 2026-10-29 · 生成时间 2026-10-31 05:30(Asia/Shanghai)| 档位:观察哨14 | 窗口 T-2 | 上游评级 C
这项研究想回答什么
α-突触核蛋白共病理是否加速 AD 的淀粉样—tau—认知级联?
方法与数据
CSF αSyn SAA + flortaucipir tau PET(Braak 分区)+ 淀粉样 PET + 领域特异认知复合分(tau PET 前后 1 年内),线性模型用异方差稳健标准误,重复 tau PET(n = 341)与认知(n = 516)用混合效应模型。
核心结论
以下所有数字均可在官方 abstract 原文(见第 7 节)中逐字核对;上游未给出的定量一律写「未给出」,不估算、不换算。
- 一句话贡献:ADNI 615 名参与者中 α-synuclein SAA 阳性 117 人(19.0%);横断面 meta-temporal tau 的 αSyn×淀粉样交互 beta 0.258(95% CI 0.023–0.493,p = 0.032),但 FDR 校正后不显著(q = 0.072),临床分期校正后衰减至 beta 0.114(p = 0.333)。
局限与未核验项
纵向部分中位随访 3.5 年(n = 341,其中 68 例阳性)未检出 αSyn×淀粉样×时间交互(meta-temporal beta -0.012,95% CI -0.046~0.023,p = 0.513);横断面主结果为名义显著且被临床分期解释掉,摘要在结论处被截断。
补全文时优先核:被截断的结论部分、阳性阈值定义、临床分期校正的具体变量、纵向子集的把握度。
⚠️ 本页为摘要级解读:未取得 PDF 全文,上述所有结论均未核至 Results/Methods;效应量、样本量、统计方法与多重比较校正在多数条目中仍未知。
对本领域的价值
给"共病理加速淀粉样-tau-认知级联"这一热门假说泼冷水,αSyn 阳性本身仍与较低执行功能相关(q = 0.032),值得共病研究者精读。
编辑研判
给一个热门假说泼了有定量的冷水:ADNI 615 人中 αSyn SAA 阳性 117 人(19.0%),横断面 αSyn×淀粉样交互 β=0.258(95% CI 0.023–0.493,p=0.032)但 FDR 后不显著(q=0.072),校正临床分期后衰减至 β=0.114(p=0.333);纵向 3.5 年随访(n=341)未检出三向交互(β=−0.012,p=0.513)。即:共病理加速级联的证据目前站不住。仍值得记的是 αSyn 阳性本身与较低执行功能相关(q=0.032)。共病研究者应精读,我的用途是给「共病理必然加速」这类默认叙事提供一个反例。
官方摘要原文(逐字,供回溯)
展开 api.biorxiv.org / api.medrxiv.org 返回的 abstract 原文
**Background:** Misfolded alpha-synuclein (alphaSyn), a common co-pathology in Alzheimer's disease, acts synergistically with amyloid and tau in animal models, but its role in the human amyloid-tau-cognition cascade is unclear. We examined whether alphaSyn modifies the amyloid-tau and tau-cognition associations, cross-sectionally and over time. **Methods:** We analyzed 615 participants from the Alzheimer's Disease Neuroimaging Initiative with a cerebrospinal fluid alphaSyn seed amplification assay (SAA), flortaucipir tau positron emission tomography (PET) in Braak stage regions, and amyloid PET and domain-specific cognitive composites within 1 year of tau PET. Linear models with heteroscedasticity-consistent standard errors tested alphaSyn x amyloid interactions on regional tau and alphaSyn x tau interactions on cognition; mixed-effects models tested the same interactions on repeated tau PET (n = 341) and cognitive testing (n = 516). **Results:** alphaSyn positivity was present in 117 participants (19.0%). Cross-sectionally, the amyloid-tau association was steeper in alphaSyn SAA+ participants for meta-temporal tau (interaction beta 0.258, 95% CI 0.023 to 0.493; p = 0.032) and Braak I-IV (p <= 0.048); no interaction survived false discovery rate correction (q = 0.072), and clinical-stage adjustment attenuated it (beta 0.114; p = 0.333). Over a median of 3.5 years (n = 341; 68 alphaSyn-positive), no alphaSyn x amyloid x time interaction was detected (meta-temporal beta -0.012, 95% CI -0.046 to 0.023; p = 0.513). No cross-sectional alphaSyn x tau interaction on cognition was detected; at mean tau, alphaSyn positivity was associated with lower executive function (q = 0.032). Longitudinally, tau-related executive decline was less steep in alphaSyn-positive participants (q = 0.042). **Conclusions:** The alphaSyn-associated amyloid-tau interaction was modest, did not withstand multiple-testing correction, and had no detected longitudinal counterpart. alphaSyn positivity was associated with poorer executive function at mean tau; the unexpected longitudinal executive interaction needs replication. These findings do not establish alphaSyn status as a marker for tau-progression enrichment in trials.
本文为预印本,未经同行评审,结论可能在正式发表时变更。生成任务 12819187(预印本全文级解读)· 上游 12784209(预印本速递)。
C 级证据分级:C 级(预印本,未经同行评审;本页为摘要级,未核至全文)
本文为预印本,未经同行评审;且本页为「摘要级」——未取得 PDF 全文(源站封锁),全部结论只依据官方 API 摘要原文。效应量、样本量、统计方法与多重比较校正在多数条目中仍未知,摘要未给出之处一律写「未给出」/「待补全文」,未做任何数值推算补全。
关于本文的文献来源:本站依据元层《预印本全文级解读_2026-10-31》(上游《预印本速递_2026-10-31》)撰写,附官方 abstract 原文供逐字回溯。